

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number  
**WO 03/089656 A1**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/00**,  
G01R 33/465, G01N 24/08

(21) International Application Number: PCT/NO03/00125

(22) International Filing Date: 15 April 2003 (15.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
20021886 19 April 2002 (19.04.2002) NO  
20023357 11 July 2002 (11.07.2002) NO

(71) Applicants (*for all designated States except US*): **AMERSHAM HEALTH AS** [NO/NO]; Intellectual Property Dept., Nycoveien 1-2, P.O. Box 4220 Nydalen, N-0401 Oslo (NO). **ARDENKJÆR-LARSEN, Jan-Henrik** [DK/DK]; Amersham Health R & D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CLARKE, Bill** [US/GB]; Amersham plc., The Grove Centre, White Lion Road, Amersham, Buckinghamshire HP7 9LL (GB). **GOLMAN, Klaes** [DK/DK]; Amersham Health R & D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE). **LERCHE, Mathilde, H.** [DK/DK]; Amersham Health R & D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE). **LOOKER, Mike** [GB/GB]; Amersham Biosciences, The Maynard Centre, MC05/K RP2, Cardiff, South Wales CF14 7YT (GB). **O'SULLIVAN, Mike** [GB/GB]; Amersham Biosciences, The Maynard Centre, MC03 CD4, Cardiff, South Wales CF14 7YT (GB). **SANTOS, Albie** [GB/GB]; Amersham Biosciences, The Maynard Centre,

MC05/K RP2, Cardiff, South Wales CF14 7YT (GB). **SERVIN, Rolf** [SE/SE]; Amersham Health R & D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE). **THANING, Mikkel** [SE/SE]; Amersham Health R & D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE).

(74) Agents: **FLECHSLER, Insa** et al.; Amersham Health AS, Nycoveien 1-2, P.O. Box 4220 Nydalen, N-0401 Oslo (NO).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHODS AND COMPOUND MIXTURES FOR DETERMINING PROTEIN ACTIVITY USING NMR SPECTROSCOPY

(57) Abstract: The invention relates to methods for determining protein activity using NMR spectroscopy. The present invention provides a method for determining protein activity *in vivo* using probe compounds and enhancing the nuclear polarisation of NMR active nuclei present in the probe compounds (hereinafter termed "hyperpolarisation") prior to NMR analysis. The invention also provides mixtures of probe compounds for the above-mentioned method.



WO 03/089656 A1